Figure 6.
A, Changes in mRNA expression levels of Nrf-2 (a), Ho-1 (b), Nqo-1 (c), Gstm (d), Mt-1 (e), Txnd1 (f), Txnl (g), Sod-1 (h), and Gstm-5 (i) in the cerebral cortex of wild-type and IL-1β KO mice exposed to acrylamide at 0, 12.5, 25 mg/kg bw for 28 days. Data are individual value plots and bars for mean ± SD (n = 6 per group). B, The extent of Nrf2 activation using ELISA test in the cerebral cortex of wild-type and IL-1β KO mice exposed to acrylamide at 0, 12.5, 25 mg/kg bw for 28 days. Data are individual value plots and bars for mean ± SD (n = 6 per group). *p < .05, **p < .01 compared with the corresponding genotype control (by Dunnett’s multiple comparison following ANOVA).

A, Changes in mRNA expression levels of Nrf-2 (a), Ho-1 (b), Nqo-1 (c), Gstm (d), Mt-1 (e), Txnd1 (f), Txnl (g), Sod-1 (h), and Gstm-5 (i) in the cerebral cortex of wild-type and IL-1β KO mice exposed to acrylamide at 0, 12.5, 25 mg/kg bw for 28 days. Data are individual value plots and bars for mean ± SD (n = 6 per group). B, The extent of Nrf2 activation using ELISA test in the cerebral cortex of wild-type and IL-1β KO mice exposed to acrylamide at 0, 12.5, 25 mg/kg bw for 28 days. Data are individual value plots and bars for mean ± SD (n = 6 per group). *p < .05, **p < .01 compared with the corresponding genotype control (by Dunnett’s multiple comparison following ANOVA).

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close